No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
Authors:
- k Con Fa BKBk Con Fa B
- Amanda B. SpurdleASAmanda B. Spurdle
- EMBRACE Study CollaboratorsECEMBRACE Study Collaborators
- Andrew J. DeansADAndrew J. Deans
- David DuffyDDDavid Duffy
- Jonathan BeesleyJBJonathan Beesley
- 10 June 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 115 (2) , 307-313
Abstract
The p27kip1 protein functions as an inhibitor of cyclin dependent kinase-2, and shows loss of expression in a large percentage of BRCA1 and BRCA2 breast cancer cases. We investigated the association between CDKN1B gene variants and breast cancer risk in 2359 female BRCA1 and BRCA2 mutation carriers from Australia, the UK, and the USA. Samples were genotyped for five single nucleotide polymorphisms, including coding variant rs2066827 (V109G). Cox regression provided no convincing evidence that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, either alone or as a haplotype. Borderline associations were observed for homozygote carriers of the rs3759216 rare allele, but were opposite in effect for BRCA1 and BRCA2 carriers (adjusted hazard ratio (HR) 0.72 (95% CI = 0.53–0.99; P = 0.04 for BRCA1, HR 1.47 (95% CI = 0.99–2.18; P = 0.06 for BRCA2). The 95% confidence intervals for per allele risk estimates excluded a twofold risk, indicating that common CDKN1B polymorphisms do not markedly modify breast cancer risk among BRCA1 or BRCA2 carriers.Keywords
This publication has 26 references indexed in Scilit:
- Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersThe American Journal of Human Genetics, 2008
- Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation SetCancer Epidemiology, Biomarkers & Prevention, 2007
- Genetic Screening Reveals an Essential Role of p27kip1 in Restriction of Breast Cancer ProgressionCancer Research, 2007
- AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 StudyCancer Epidemiology, Biomarkers & Prevention, 2007
- Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosisBMC Cancer, 2007
- p27 Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant ChemotherapyJNCI: Journal of the National Cancer Institute, 2006
- Molecular Analysis of the P27/Kip1 Gene in Breast CancerMolecular Diagnosis, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Association between the V109G Polymorphism of thep27Gene and the Risk and Progression of Oral Squamous Cell CarcinomaClinical Cancer Research, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003